Non-small Cell Lung Cancer Metastatic Clinical Trial
Official title:
A Randomized, Phase IIB/III Study of Ganetespib (STA-9090) in Combination With Docetaxel Versus Docetaxel Alone in Subjects With Stage IIIb or IV Non-Small-Cell Lung Cancer
The purpose of this study is to determine whether combining ganetespib (STA-9090) with docetaxel is more effective than docetaxel alone in the treatment of subjects with advanced non-small cell lung cancer.
Preliminary signals of clinical activity of ganetespib as a single agent have been observed in NSCLC. A novel approach to treatment of NSCLC is the combination of Hsp90 inhibitors, such as ganetespib, and taxanes. Such combinations have shown potential for synergy in preclinical and clinical evaluations with other Hsp90 inhibitors. Preclinical studies with ganetespib and taxanes have indicated that the combination of these drugs was more effective than either drug alone at inducing cell death, and an ongoing phase 1 study indicates that the combination is well tolerated and warrants systematic evaluation in a larger study. ;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01523340 -
A Prospective Observational Study Evaluating c-MET Expression and EGFR Gene Mutation Correlation With Erlotinib Response
|
||
| Recruiting |
NCT03956641 -
Evolution of the Physical Condition in Treated Cancer Patients
|
N/A | |
| Active, not recruiting |
NCT02035683 -
PET/CT Scan as a Tool to Rationalize the Treatment of of Advanced NSCLC Patients Undergoing First Chemotherapy
|
N/A | |
| Completed |
NCT01848613 -
Study of Patient Preference for Oral or Intravenous Vinorelbine in the Treatment of Advanced NSCLC
|
Phase 4 | |
| Suspended |
NCT01320501 -
Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer
|
Phase 4 | |
| Terminated |
NCT01471964 -
Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06127940 -
K-SAB Trial - Sotorasib Followed by SBRT to 1-3 Lesions in Advanced NSCLC With KRASG12C Mutation
|
Phase 1 | |
| Terminated |
NCT04069936 -
Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC
|
Phase 2 | |
| Terminated |
NCT03445000 -
ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer
|
Phase 2 | |
| Terminated |
NCT03386929 -
Survival Prolongation by Rationale Innovative Genomics
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02922764 -
A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer
|
Phase 1 | |
| Terminated |
NCT01574300 -
Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network
|
||
| Active, not recruiting |
NCT04646824 -
Almonertinib With Chemotherapy in mEGFR NSCLC
|
Phase 2 | |
| Completed |
NCT01966003 -
Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer
|
Phase 3 | |
| Recruiting |
NCT03656094 -
Chemotherapy With Pembrolizumab Continuation After Progression to PD-1/L1 Inhibitors
|
Phase 2 | |
| Active, not recruiting |
NCT03469960 -
Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr
|
Phase 3 | |
| Recruiting |
NCT05919264 -
FOG-001 in Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT04793815 -
Lung Cancer Cryo-Activation as a Novel Approach to Augment Immunotherapy Efficacy (CRYOVATE)
|
N/A | |
| Terminated |
NCT01380795 -
Feasibility of the Research for Mutation of K-ras and EGFR in CTCs From Metastatic Non Small Cells Bronchial Carcinomas
|
Early Phase 1 | |
| Completed |
NCT02959619 -
Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALK
|
Phase 1 |